安帝君斯 AGEN 深 沪
等待开盘 04-02 09:30:00 美东时间
3.40
+0.060
+1.80%
华盛通- 最 高3.495
- 今 开3.40
- 成交量 32.49万股
- 最 低 3.375
- 昨 收 3.34
- 总市值 1.31亿
- 52周最高 7.34
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 1.60
- 委 比 -60.10%
- 总股本 3839.84万
- 历史最高 202.5868
- 量 比 1.10
- 振 幅 3.59%
- 历史最低 1.38
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Agenus Securities Class Action Dismissed, Legal Risks Ease
Agenus ( ($AGEN) ) has issued an update. On March 24, 2026, the U.S. District C...
03-26 20:59
Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend
Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend On March 24, 2026, a federal court in Massachusetts issued an order in a putative securities class action against Agenus and several executives. The case is Byron Olsen v. Agenus, et al., Civil Action
03-26 20:25
Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026
A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapyAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that
03-18 04:40
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
Agenus Triggers First $20M Contingent Payment Under Prior Collaboration Deal With Zydus Lifesciences
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus
03-10 19:34
Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL Associated With Systemic Inflammation In Blood, Tumor Immune Activity Within Tumor Microenvironment
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an Fc-enhanced
02-20 04:17
Agenus Inc. Publishes Findings on Systemic and Tumor-Microenvironment Inflammation in Botensilimab-Treated Cold, Refractory Tumors
Agenus Inc. Publishes Findings on Systemic and Tumor-Microenvironment Inflammation in Botensilimab-Treated Cold, Refractory Tumors Agenus Inc. published a medical research presentation on how systemic inflammation and tumor-microenvironment immune features are associated with outcomes in patients wi
02-20 04:17
Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab
Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (an Fc-enhanced anti-CTLA-4 ant
02-20 04:15
Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold Tumors
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation
02-10 02:04
Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor
Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor Agenus Inc. hat angekündigt, neue translationale und klinische Biomarker-Analysen aus dem Botensilimab (BOT)-Immuntherapieprogramm auf der American Association for Cancer Research–Immuno-Oncology (AACR-IO) Konfere
02-10 02:00
